JP2014511393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511393A5 JP2014511393A5 JP2013557763A JP2013557763A JP2014511393A5 JP 2014511393 A5 JP2014511393 A5 JP 2014511393A5 JP 2013557763 A JP2013557763 A JP 2013557763A JP 2013557763 A JP2013557763 A JP 2013557763A JP 2014511393 A5 JP2014511393 A5 JP 2014511393A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- effective amount
- therapeutically effective
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 239000013543 active substance Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 3
- -1 3-ethoxy-4-methoxyphenyl Chemical group 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229960002986 dinoprostone Drugs 0.000 claims 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 125000002575 PGE2 group Chemical group 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449716P | 2011-03-07 | 2011-03-07 | |
| US61/449,716 | 2011-03-07 | ||
| PCT/US2012/027368 WO2012121988A2 (en) | 2011-03-07 | 2012-03-02 | Methods for treating diseases using isoindoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511393A JP2014511393A (ja) | 2014-05-15 |
| JP2014511393A5 true JP2014511393A5 (https=) | 2015-04-16 |
Family
ID=45852726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557763A Pending JP2014511393A (ja) | 2011-03-07 | 2012-03-02 | イソインドリン化合物を用いた疾患の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9387195B2 (https=) |
| EP (2) | EP2683376B1 (https=) |
| JP (1) | JP2014511393A (https=) |
| ES (2) | ES2711100T3 (https=) |
| WO (1) | WO2012121988A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013328695B9 (en) * | 2012-10-11 | 2018-05-17 | Nerre Therapeutics Limited | Novel uses |
| EP3539539B1 (en) * | 2013-06-17 | 2025-11-05 | Amgen (Europe) GmbH | Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| RU2538615C1 (ru) * | 2013-08-20 | 2015-01-10 | Общество с ограниченной ответственностью "УНИФАРМ" (ООО "УНИФАРМ"). | Средство для профилактики и лечения простатита и аденомы предстательной железы |
| CN105669478A (zh) * | 2014-11-17 | 2016-06-15 | 重庆医药工业研究院有限责任公司 | 一种制备3-氨基邻苯二甲酸及其衍生物的方法 |
| WO2016105499A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| US10399942B2 (en) * | 2015-11-19 | 2019-09-03 | Alembic Pharmaceuticals Limited | Process and novel polymorphic form of Apremilast |
| CN105388237B (zh) * | 2015-12-28 | 2017-02-01 | 成都百裕金阁莱药业有限公司 | 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法 |
| EA038882B1 (ru) * | 2016-03-30 | 2021-11-02 | Сарудбхава Формулатионс Приват Лимитед | Фармацевтическая композиция апремиласта |
| US20180325931A1 (en) * | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| CN110352052A (zh) * | 2017-01-27 | 2019-10-18 | 萨鲁德巴瓦制剂私人有限公司 | 阿普斯特的局部治疗组合物 |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| EP3853204A4 (en) * | 2018-09-21 | 2022-06-22 | Apramitha Innovations Private Limited | IMPROVED AND STABLE APREMILAST PHARMACEUTICAL COMPOSITIONS |
| CN113271964A (zh) | 2019-01-11 | 2021-08-17 | 诺华股份有限公司 | 化脓性汗腺炎治疗中使用的抗cd40抗体 |
| CN115068406A (zh) * | 2021-03-12 | 2022-09-20 | 浙江万晟药业有限公司 | 一种用于治疗斑秃的阿普斯特凝胶及其制备工艺 |
| JPWO2023120466A1 (https=) * | 2021-12-23 | 2023-06-29 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| US7893101B2 (en) * | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| PT1511516E (pt) * | 2002-05-28 | 2009-02-20 | Nycomed Gmbh | Preparação farmacêutica para aplicação tópica |
| WO2004009776A2 (en) * | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| KR20050053694A (ko) | 2002-09-27 | 2005-06-08 | 얀센 파마슈티카 엔.브이. | 3, 4-이치환된 피롤 및 염증 질환을 치료하기 위한 그의용도 |
| BRPI0418801A (pt) * | 2004-05-05 | 2007-10-16 | Celgene Corp | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit |
| DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| KR20070092276A (ko) | 2004-12-13 | 2007-09-12 | 셀진 코포레이션 | Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도 |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| US7550505B2 (en) * | 2006-07-24 | 2009-06-23 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| JP2010523725A (ja) * | 2007-04-16 | 2010-07-15 | レオ ファーマ アクティーゼルスカブ | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン |
| EP2276483B1 (en) | 2008-03-27 | 2014-05-07 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| HRP20160488T1 (hr) * | 2008-12-19 | 2016-06-17 | Leo Pharma A/S | Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti |
| WO2010091894A2 (en) * | 2009-02-16 | 2010-08-19 | Giuliani International Limited | Methods of treating hair related conditions |
| AU2009349135A1 (en) * | 2009-06-30 | 2012-02-16 | Piramal Enterprises Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
| EP2498753B1 (en) * | 2009-11-10 | 2019-03-06 | Celgene Corporation | Nanosuspension of a poorly soluble drug made by microfluidization process |
-
2012
- 2012-03-02 ES ES12709437T patent/ES2711100T3/es active Active
- 2012-03-02 ES ES17208060T patent/ES2868231T3/es active Active
- 2012-03-02 EP EP12709437.3A patent/EP2683376B1/en active Active
- 2012-03-02 WO PCT/US2012/027368 patent/WO2012121988A2/en not_active Ceased
- 2012-03-02 US US14/003,750 patent/US9387195B2/en active Active
- 2012-03-02 EP EP17208060.8A patent/EP3320902B1/en not_active Revoked
- 2012-03-02 JP JP2013557763A patent/JP2014511393A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511393A5 (https=) | ||
| JP2014516942A5 (https=) | ||
| JP2009522289A5 (https=) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2013155188A5 (https=) | ||
| HRP20211644T1 (hr) | Liječenje ili prevencija kardiovaskularnih događaja administracijom kolhicina | |
| JP2012515184A5 (https=) | ||
| FI3865484T3 (fi) | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon | |
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| JP2012517427A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013540766A5 (https=) | ||
| JP2015515985A5 (https=) | ||
| JP2013538853A5 (https=) | ||
| JP2015537009A5 (https=) | ||
| ME02474B (me) | Terapijski režimi | |
| Paz-Ares et al. | Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebo-controlled MISSION trial | |
| JP2019530706A5 (https=) | ||
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| EP2606887A4 (en) | DIINDOLYLMETHANE AND PRECURSORS AND DERIVATIVES THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LIVER DISEASES | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| FI3302451T3 (fi) | Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| HK1252411A1 (zh) | 磷脂酰肌醇3-激酶抑制剂的给药方案 |